The combination of the BCL2 inhibitor venetoclax (VEN) and azacitidine (AZA) has changed the paradigm of treatment for elderly or unfit acute myeloid leukemia (AML) patients. The gene discussed is BCL2; the disease is acute myeloid leukemia.